Neparvis

sacubitril / valsartan

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Neparvis. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Neparvis.

For practical information about using Neparvis, patients should read the package leaflet or contact their doctor or pharmacist.

What is Neparvis and what is it used for?

Neparvis is a heart medicine that contains the active substances sacubitril and valsartan. It is used in adults with long-term heart failure who have symptoms of the disease. Heart failure is the inability of the heart to pump enough blood around the body.

This medicine is the same as Entresto, which is already authorised in the European Union (EU). The company that makes Entresto has agreed that its scientific data can be used for Neparvis (‘informed consent’).

How is Neparvis used?

Neparvis is available as tablets (24 mg sacubitril / 26 mg valsartan, 49 mg sacubitril / 51 mg valsartan, and 97 mg sacubitril / 103 mg valsartan). Neparvis can only be obtained with a prescription.

Neparvis tablets are taken twice a day. The recommended starting dose is one tablet of Neparvis 49 mg / 51 mg twice a day and the dose is then doubled after 2 to 4 weeks to 97 mg / 103 mg twice a day. The doctor may choose lower doses for certain patients. For further information, see the summary of product characteristics (also part of the EPAR).

How does Neparvis work?

The two active substances in Neparvis, sacubitril and valsartan, work in different ways. Sacubitril blocks the breakdown of natriuretic peptides produced in the body. Natriuretic peptides cause sodium and water to pass into the urine thereby reducing the strain on the heart. Natriuretic peptides also reduce blood pressure and protect the heart from developing fibrosis (scar tissue) that occurs in heart failure.

Valsartan is an ‘angiotensin-II-receptor antagonist’, which means that it blocks the action of a hormone called angiotensin II. The effects of angiotensin II can be harmful in patients with heart failure. By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone’s harmful effects on the heart and it also reduces blood pressure by allowing blood vessels to widen.

What benefits of Neparvis have been shown in studies?

Neparvis has been shown to be effective in treating heart failure in one main study. In the study, Neparvis was compared to enalapril, another medicine used for heart failure. Patients in the study had long-term heart failure with symptoms of the disease and reduced ejection fraction (the proportion of blood leaving the heart). In the group treated with Neparvis, 21.8% (914 of 4,187) patients either died as a result of heart and circulation problems or were admitted to hospital with heart failure compared to 26.5% (1,117 of 4,212) patients treated with enalapril. In general, patients were monitored for about 27 months, during which they took the medicine for about 24 months on average. The study was stopped early because there was compelling evidence that Neparvis was more effective than enalapril.

What are the risks associated with Neparvis?

The most common side effects with Neparvis (which may affect more than 1 in 10 people) are high blood potassium levels, low blood pressure and the kidneys working less well. A potentially severe side effect, angioedema (rapid swelling of deeper skin tissues as well as the tissues around the throat, causing breathing difficulty), can occur uncommonly (affecting fewer than 1 in 100 people). For the full list of all side effects reported with Neparvis, see the package leaflet.

Neparvis must not be taken with medicines known as ACE inhibitors (which are used to treat heart failure and high blood pressure). It must not be taken by patients who have suffered angioedema, those who have severe liver disease or by women who are pregnant. For the full list of restrictions see the package leaflet.

Why is Neparvis approved?

The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Neparvis are greater than its risks and recommended that it be approved for use in the EU. The main study found that Neparvis reduced deaths from heart and circulation problems or hospital admissions for heart failure.

The serious side effects of Neparvis in the main study were similar to those of enalapril, which is already authorised for use in heart failure. Valsartan, one of the active substances in the medicine, is well established for the treatment of high blood pressure and heart failure; its side effects are well known.

What measures are being taken to ensure the safe and effective use of Neparvis?

A risk management plan has been developed to ensure that Neparvis is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Neparvis, including the appropriate precautions to be followed by healthcare professionals and patients.

Other information about Neparvis

The European Commission granted a marketing authorisation valid throughout the European Union for Neparvis on 26 May 2016.

For more information about treatment with Neparvis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Neparvis : EPAR - Summary for the public BG = bălgarski 2016-06-13  
Neparvis : EPAR - Summary for the public ES = español 2016-06-13  
Neparvis : EPAR - Summary for the public CS = čeština 2016-06-13  
Neparvis : EPAR - Summary for the public DA = dansk 2016-06-13  
Neparvis : EPAR - Summary for the public DE = Deutsch 2016-06-13  
Neparvis : EPAR - Summary for the public ET = eesti keel 2016-06-13  
Neparvis : EPAR - Summary for the public EL = elliniká 2016-06-13  
Neparvis : EPAR - Summary for the public EN = English 2016-06-13  
Neparvis : EPAR - Summary for the public FR = français 2016-06-13  
Neparvis : EPAR - Summary for the public IT = italiano 2016-06-13  
Neparvis : EPAR - Summary for the public LV = latviešu valoda 2016-06-13  
Neparvis : EPAR - Summary for the public LT = lietuvių kalba 2016-06-13  
Neparvis : EPAR - Summary for the public HU = magyar 2016-06-13  
Neparvis : EPAR - Summary for the public MT = Malti 2016-06-13  
Neparvis : EPAR - Summary for the public NL = Nederlands 2016-06-13  
Neparvis : EPAR - Summary for the public PL = polski 2016-06-13  
Neparvis : EPAR - Summary for the public PT = português 2016-06-13  
Neparvis : EPAR - Summary for the public RO = română 2016-06-13  
Neparvis : EPAR - Summary for the public SK = slovenčina 2016-06-13  
Neparvis : EPAR - Summary for the public SL = slovenščina 2016-06-13  
Neparvis : EPAR - Summary for the public FI = suomi 2016-06-13  
Neparvis : EPAR - Summary for the public SV = svenska 2016-06-13  
Neparvis : EPAR - Summary for the public HR = Hrvatski 2016-06-13  

This EPAR was last updated on 26/10/2016 .

Authorisation details

Product details

Product details for Neparvis
NameNeparvis
Agency product numberEMEA/H/C/004343
Active substance

sacubitril / valsartan

International non-proprietary name (INN) or common name

sacubitril / valsartan

Therapeutic area Heart Failure
Anatomical therapeutic chemical (ATC) code C09DX04
Additional monitoring

This medicine is under additional monitoring. This means that it is being monitored even more intensively than other medicines. For more information, see medicines under additional monitoring.

Publication details

Publication details for Neparvis
Marketing-authorisation holder

Novartis Europharm Ltd

Revision2
Date of issue of marketing authorisation valid throughout the European Union26/05/2016

Contact address:

Novartis Europharm Ltd
Frimley Business Park 
Camberley 
GU16 7SR 
United Kingdom

Product information

Product information

21/09/2016  Neparvis -EMEA/H/C/004343 -IB/0004/G

Name Language First published Last updated
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05
Neparvis : EPAR - Product Information HR = Hrvatski 2016-06-13 2016-10-05

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  
Neparvis : EPAR - All Authorised presentations HR = Hrvatski 2016-06-13  

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Neparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Neparvis : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2016-10-05 2016-10-26

Initial marketing-authorisation documents

Name Language First published Last updated
Neparvis : EPAR - Public assessment report HR = Hrvatski 2016-06-13  
CHMP summary of opinion for Neparvis HR = Hrvatski 2016-04-01  

Authorised

This medicine is approved for use in the European Union